About this ETF
The Invesco S&P 100 Equal Weight ETF seeks to track the investment results of the S&P 100 Equal Weight Index. This particular index applies an equal-weighting methodology to the constituent companies of the broader S&P 100 Index. The Fund aims to allocate at least 90% of its total assets to the securities comprising this index, with both the Fund and the underlying index undergoing quarterly rebalancing. As of August 31, 2025, the ETF boasted an impressive 5-star overall rating from Morningstar Inc., positioning it among the top 10% of 1077 funds in its category. Its strong performance was also recognized with a 5-star rating for the 3-year period (out of 1077 funds) and the 10-year period (out of 826 funds), alongside a 4-star rating for the 5-year period (out of 1018 funds). Morningstar determines these ratings using a risk-adjusted return measure that emphasizes consistent performance and accounts for monthly performance variations, particularly downward movements. For comparative purposes, open-end mutual funds and exchange-traded funds are assessed together, with a minimum three-year history required for rating eligibility. The overall star rating is a weighted average of the 3-, 5-, and 10-year metrics, where applicable, incorporating fees and expenses but excluding sales charges. It is crucial to remember that past performance offers no guarantee of future returns. Ratings are subject to monthly adjustments and are derived from Morningstar's proprietary data. Had fees not been waived or expenses reimbursed in the past, the Morningstar rating could have been lower. Additionally, ratings for different share classes may vary due to distinct performance characteristics. Morningstar allocates five stars to the top 10% of funds in a category, four stars to the subsequent 22.5%, three stars to the middle 35%, two stars to the following 22.5%, and one star to the bottom 10%.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +3.63% | +5.80% | +10.45% | +14.15% | +19.56% | +18.48% | +10.05% | +12.49% | +8.90% |
| Total return | +3.63% | +6.23% | +11.40% | +15.13% | +21.62% | +20.71% | +12.22% | +14.76% | +10.93% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 26, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.30% | Annual cost of a $10,000 investment | $30.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 26, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 104 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Booking Holdings Inc | BKNG | 1.24% | 168.18K | $36.0M |
| 2 | Palantir Technologies Inc | PLTR | 1.24% | 207.45K | $35.8M |
| 3 | Merck & Co Inc | MRK | 1.23% | 226.82K | $35.5M |
| 4 | Amgen Inc | AMGN | 1.22% | 79.95K | $35.4M |
| 5 | Thermo Fisher Scientific Inc | TMO | 1.22% | 56.02K | $35.2M |
| 6 | Abbott Laboratories | ABT | 1.22% | 302.95K | $35.2M |
| 7 | Charles Schwab Corp/The | SCHW | 1.18% | 302.62K | $34.0M |
| 8 | Intuit Inc | INTU | 1.18% | 95.01K | $34.0M |
| 9 | Microsoft Corp | MSFT | 1.16% | 67.99K | $33.4M |
| 10 | Mastercard Inc | MA | 1.15% | 55.24K | $33.1M |
| 11 | Gilead Sciences Inc | GILD | 1.15% | 222.36K | $33.1M |
| 12 | Bristol-Myers Squibb Co | BMY | 1.14% | 485.82K | $33.0M |
| 13 | Capital One Financial Corp | COF | 1.14% | 152.06K | $32.9M |
| 14 | Salesforce Inc | CRM | 1.13% | 158.05K | $32.5M |
| 15 | ServiceNow Inc | NOW | 1.12% | 254.68K | $32.3M |
| 16 | Visa Inc | V | 1.11% | 83.63K | $32.1M |
| 17 | RTX Corp | RTX | 1.11% | 152.25K | $32.0M |
| 18 | AbbVie Inc | ABBV | 1.10% | 120.07K | $31.9M |
| 19 | Danaher Corp | DHR | 1.10% | 147.12K | $31.8M |
| 20 | Adobe Inc | ADBE | 1.10% | 115.73K | $31.7M |
| 21 | Uber Technologies Inc | UBER | 1.10% | 393.70K | $31.6M |
| 22 | Bank of New York Mellon Corp/The | BNY | 1.09% | 193.26K | $31.6M |
| 23 | Blackrock Inc | BLK | 1.09% | 26.76K | $31.5M |
| 24 | Union Pacific Corp | UNP | 1.08% | 101.14K | $31.3M |
| 25 | JPMorgan Chase & Co | JPM | 1.08% | 87.35K | $31.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.51% | Paid (last 12 months) | $2.0382 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 22, 2026 | Last payment | $0.5148 (Jun 26, 2026) |
| Growth 1Y | +5.56% | Growth 3Y / 5Y (ann.) | +7.97% / +8.77% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 22, 2026 | Jun 22, 2026 | Jun 26, 2026 | $0.5148 |
| Mar 23, 2026 | Mar 23, 2026 | Mar 27, 2026 | $0.5285 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $0.5166 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 26, 2025 | $0.4784 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 27, 2025 | $0.4431 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 28, 2025 | $0.5309 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 27, 2024 | $0.4711 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 27, 2024 | $0.4858 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.4783 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 22, 2024 | $0.4668 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 22, 2023 | $0.4515 |
| Sep 18, 2023 | Sep 19, 2023 | Sep 22, 2023 | $0.4288 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 10.67% / 13.07% | Sharpe 1Y / 3Y | 1.75 / 1.39 |
| Max drawdown 1Y / 3Y | -7.77% / -14.95% | Sortino 1Y | 2.64 |
| Beta vs S&P 500 (3Y) | 0.764 | Correlation vs S&P 500 (1Y) | 0.838 |
| Downside deviation 1Y | 7.09% | Risk-free rate used | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 27, 2026. Formulas →
Liquidity
| Volume today | 64.10K | Average volume | 85.36K |
| AUM | $2.89B | Premium/Discount | -0.13% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $23.8M | +0.83% | $2.86B → $2.89B |
| 1 Week | $67.2M | +2.39% | $2.81B → $2.89B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for EQWL
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
EQWL